EXP3174: The major active metabolite of losartan

Cardiovascular Drug Reviews

Volumn 15, Issue 2, 1997, Pages 122-136

  Tamaki, Toshiaki ^a   Nishiyama, Akira ^b   Kimura, Shoji ^b   Aki, Yasuharu ^b   Yoshizumi, Masanori ^a   Houchi, Hitoshi ^a   Morita, Kyoji ^a   Abe, Youichi ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 receptor antagonist; EXP3174; Losartan

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; CYTOCHROME P450; DRUG METABOLITE; LOSARTAN; RECEPTOR SUBTYPE;

ANTIHYPERTENSIVE ACTIVITY; CHILL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW;

EID: 0030864553     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1997.tb00327.x     Document Type: Review

References (70)

1. Abe Y, Kishimoto T, Yamamoto K, Effect of angiotensin II antagonist infusion on autoregulation of renal blood flow. Am J Physiol 1976;231:1267-1271.
2. Bartholomeusz B, Widdop R. Effect of acute and chronic treatment with the angiotensin II subtype 1 receptor antagonist EXP3174 on baroreflex function in conscious spontaneously hypertensive rats. J Hypertens 1995;13:219-225.
3. Basso N, Kurnjek M, Ruiz P, Cannata M. Effect of EXP3174 on blood pressure of normoreninemic renal hypertensive rats. Hypertension 1995;25:283-287.
4. Bauer J, Reams G. The angiotensin II type 1 receptor antagonists. Arch Intern Med 1995;155:1361-1368.
5. Brooks D, Fredrickson T, Weinstock J, Ruffolo R, Edwards R, Gellai M. Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs. Naunyn-Schmiedeberg's Arch Pharmacol 1992;345:673-678.
6. Brooks DP, DePalma PD, Ruffolo RR. Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis. J Pharmacol Exp Ther 1992;263:422-427.
7. Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature for angiotensin receptors: A report of the nomenclature committee of the council for high blood pressure research. Hypertension 1991;17:720-723.
8. Cambien F, Soubrier F. The angiotensin-converting enzyme: Molecular biology and implication of the gene polymorphism in cardiovascular diseases. In: Laragh J, Brenner B, eds. Hypertension: Pathophysiology, Diagnosis, and Management, New York:Raven Press, 1995:1667-1682.
9. Chang R, Siegl P, Clineschmidt B, et al. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. J Pharmacol Exp Ther 1992;262:133-138.
10. Chansel D, Badre L, Czekalski S, Vandermeersch S, Cambar J, Ardaillou R. Intrinsic properties of the nonpeptide angiotensin II antagonist losartan in glomeruli and mesangial cells at high concentrations. J Pharmacol Exp Ther 1993;265:1534-1543.
11. Chiu AT, McCall DE, Price WA, et al. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP753, an orally active andhypertensive agent. J Pharmacol Exp Ther 1990;252:711-718.
12. Christ D. Human plasma protein binding of the angiotensin EE receptor antagonist losartan potassium (Dup753/MK954) and its pharmacologically active metabolite EXP3174. J Clin Pharamacol 1995;35:515-520.
13. Christ D, Wong N, Lam G, Quon C. Pharmacokinetics of the novel angiotensin II receptor antagonist DuP753 in dogs. FASEB J 1990;4:A462.
14. Christ DD, Wong PC, Wong YN, Hart SD, Quon CY, Lam GN. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (Dup753/MK954) in the dog. J Pharmacol Exp Ther 1994;268:1199-1205.
15. Christen Y, Waeber B, Nussberger J, et al. Oral administration of Dup753, a specific angiotensin II receptor antagonist, to normal male volunteers inhibition of pressor response to exogenous angiotensin I and II Circulation 1991;83:1333-1342.
16. Dickinson K, Cohen R, Skwish S, et al. BMS-1080560, an insurmoutable inhibitor of angiotensin II-stimulated responses: Comparison with losartan and EXP3174. Br J Pharmacol 1994;113:379-189.
17. Edwards R, Trizna W, Stack E, Weinstock J. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J Pharmacol Exp Ther 1996;276:125-129.
18. Fenoy FJ, Scicli G, Carretero O, Roman RJ. Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 1991;17:1038-1044.
19. Furtek C, Lo M. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high performance liquid chromatography. J Chromato 1992; 573:295-301.
20. Furukawa Y, Kishimoto S, Nishikawa K. Jpn. Patent No. 56-71073, 71074 (1981); U.S. Pat. 4340598, 4355040 (1982).
21. Furukawa Y, Nishikawa K. Jpn. Patent No. 58-157768 (1983); U.S. Pat. 504049 (1983).
22. Goldberg M, Beck LH, Puschett JB. Sites of action benzothiazines, furosemide and ethacynic acid. In: Lant AJ, Wilson GM. eds. Modern Diuretic Therapy. Amsterdam:Excepta Medica, 1973:135-147.
23. 1-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 1995;49:115-119.
24. Goldberg M, Lo M, Deutsch P, Wilson S, McWilliams E, McCrea J. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 1996;59:268-274.
25. Gunning M, Ingelfinger J, King A, Brenner B. Vasoactive peptides and the kidney. In: Brenner B, ed. The Kidney. Philadelphia: W.B. Saunders, 1996:627-712.
26. Hajj-ali AF, Zimmerman BG. Kinin contribution to renal vasodilator effect of captopril in rabbit. Hypertension 1991;17:504-509.
27. Hall JE. Regulation of glomerular filtration rate and sodium excretion by angiotensin II. FASEB J 1986; 45:1431-1437.
28. Harris PJ, Navar LG. Tubular transport responses to angiotensin. Am J Physiol 1985;248:F621-F630.
29. Hatch M, Freel R, Shahinfar F, Vaziri N. Effects of the specific angiotensin EI receptor antagonist losartan on urate homeostasis and intestinal urate transport. J Pharmacol Exp Ther 1996;276:187-193.
30. Higashio T, Abe Y, Yamamoto K. Renal effects of bumetanide. J Pharmacol Exp Ther 1978;207:212-220.
31. Ichikawa I. Angiotensin actions in the kidney: Renewed insight into the old hormone. Kidney Im 1991;40: 583-596.
32. Ishizaki H, Ohtawa M. Inhibitory effect of the nonpeptide angiotensin II receptor antagonist losartan and its active metabolite, E-3174, on cAMP phosphodiesterase: Additional action of the antagonists. Biochem Pharmacol 1994;48:201-204.
33. Jackson E, Garrison J. Renin and angiotensin. In: Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A, eds. The Pharmacological Basis of Therapeutics. New York:McGraw-Hill, 1996:733-758.
34. Lo M, Goldberg M, McCrea J, Lu H, Furtek C, Bjornsson T. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-649.
35. McMahon T, Kaye A, Hood J, Minkes R, Nossaman B, Kadowitz P. Inhibitory effects of DuP753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat. Appl Physiol 1992;73:2054-2061.
36. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51: 513-521.
37. Nagura J, Yasuda S, Fujishima K, et al. Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist. Eur J Pharmacol 1995;274:201-211.
38. Nakamura A, Iwao H, Fukui K, et al. Regulation of liver angiotensinogen and kidney renin mRNA levels by angiotensin II. Am J Physiol 1990;258:E1-E6.
39. Nakashima M, Uematsu T, Kosuge K, Kanamura M. Pilot study of the uricosuric effect of DuP753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-335.
40. Nishikawa K, Shibouta Y, Inada Y, Terashita Z, Kawazoe K, Furukawa Y. Nonpeptide angiotensin II receptor antagonists: Pharmacological studies on imidazoleacetic acid derivatives. J Takeda Res Lab 1991; 50:75-98.
41. Nishiyama A, Tamaki T, Masumura H, et al. Effects of semotiadil fumarate (SD-3211) on renal hemodynamics and function in dogs. Eur J Pharmacol 1992;218:311-317.
42. Noda M, Shibouta Y, Inada Y, et al. Inhibition of rabbit aortic angiotensin II(AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993;46:311-318.
43. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-297.
44. Osei S, Minkes R, Bellan J, Kadowitz P. Analysis of the inhibitory effects of DuP753 and EXP3174 on responses to angiotensin II in the feline hindquarters vascular bed. J Pharmacol Exp Ther 1993;264:1104-1112.
45. Pals D, Masucci F, Sipos F, Denning G. A specific competitive antagonist of the vascular action of angiotensin II. Circ Res 1971;29:664-672.
46. Richard V, Berdeaux A, Giudicelli J. Systemic and coronary effects of the angiotensin II receptor antagonist EXP3174 in dogs. J Cardiovasc Pharmacol 1993;22:52-57.
47. Richard V, Ghaleh B, Berdeax A, Giudicelli J. Comparison of the effects of EXP3174, an angiotensin II antagonist, and enalaprilat on myocardial infarct size in anesthetized dogs. Br J Pharmacol 1993;110:969-974.
48. Sachinidis A, Ko Y, Weisser P, et al. EXP3174, a metabolite of losartan (MK954, DuP753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertension 1993;11:155-162.
49. Seldin DW, Eknoyan G, Suki WN, Rector FC. Localization of diuretic action from the pattern of water and electrolyte excretion. Ann NY Acad Sci 1966;139:328-343.
50. Shibouta Y, Inada Y, Ojima M, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993;266:114-120.
51. Sica D, Lo M, Shaw W, et al. Pharmacokinetics of losartan in renal insufficiency. J Hypertens (Suppl 1) 1995;13:549-552.
52. Stearns R, Chakravarty P, Chen R, Chiu S. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995;23:207-215.
53. Stearns R, Miller R, Doss G, et al. The metabolism of DuP753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 1992;20:281-287.
54. Streeten DHP, Anderson GHJ. Angiotensin-receptor blocking drugs. In: Birkennhager WH, Reid JL, eds. Handbook of Hypertension. Amsterdam:Elsevier, 1984:246-271.
55. Suki W, Rector FC, Seldin DW. The site of action of furosemide and other sulfonamide diuretics in the dog. J Clin Invest 1965;44:1458-1469.
56. Sweet C, Bradstreet D, Berman R, Jallard N, Saenz A, Weidler D. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994;7:1035-1040.
57. Tamaki T, Nishiyama A, Yoshida H, et al. Effects of EXP3174, a non-peptide angiotensin II receptor antagonist, on renal hemodynamics and renal function in dogs. Eur J Pharmacol 1993;236:15-21.
58. Timmermans P, Carini D, Chiu A, et al. Angiotensin II receptor antagonists. From discovery to antihypertensive drugs. Hypertension (Suppl III) 1991;18:136-142.
59. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
60. Tsunoda L, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:28-32.
61. Weber M. Clinical experience with the angiotensin II receptor antagonist losartan: A preliminary report. Am J Hypertens 1992;5:247S-251S
62. 1-receptor antagonists, losartan and EXP3174, in water-derived Brattleboro rats. Br J Pharmacol 1993; 108:684-688.
63. Wong PC, Hart SD, Duncia JV, Timmermans PBWM. Nonpeptide angiotensin II receptor antagonists. Studies with Dup 753 and EXP3174 in dogs. Eur J Pharmacol 1991;202:323-330.
64. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:726-732.
65. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:719-725.
66. Wong PC, Price WA, Chiu AT, et al. Hypotensive action of Dup 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension 1990;15:459-468.
67. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of Dup 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255:211-217.
68. Wong PC, Price WA, Chui AT, et al. Nonpeptide angiotensin II receptor antagonists, studies with EXP9270 and DuP753. Hypertension 1990;15:823-834.
69. Yun C, Lee H, Lee H, Rho J, Jeong H, Guengerich F. Oxidation of the angiotensin II receptor antagonist losartan (DuP753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 1995;23:285-289.
70. Zusman RM. Renin- and non-renin-mediated antihypertensive actions of converting enzyme inhibitors. Kidney Int 1984;25:969-983.